Joe Laning
Southborough, Massachusetts, United States
573 followers
500+ connections
About
SCIENTIFIC LEADER IN PRODUCT DEVELOPMENT AND CELL THERAPEUTICS MANUFACTURING
A highly…
Activity
573 followers
Experience
-
Astellas Pharma US
Education
Publications
-
Human immune system development and survival of non-obese diabetic (NOD)-scid IL2rγ null (NSG) mice engrafted with human thymus and autologous haematopoietic stem cells.
Clin Exp Immunol 174(3):372-88
Other authors -
-
Parameters for Establishing Humanized Mouse Models to Study Human Immunity: Analysis of Human Hematopoietic Stem Cell Engraftment in Three Immunodeficient Strains of Mice Bearing the IL2rnull Mutation
Clin. Immunol. 2010, 135(1):84.
Other authors -
-
Ex Vivo Expanded CD34+ Human Umbilical Cord Blood Cells Generate Multiple Lymphohematopoietic Lineages in NOD-scid IL2r null Mice.
Exp. Biology and Med. 2008. 233(8):997.
Other authors -
Patents
-
System for Immunotherapy Targeting Tumor Propagation and Progression
Issued US US009977025B2
Finding biologically relevant cancer markers is key to developing an effective treatment. Once specific antigens have been identified that are present on the cell population responsible for propagating tumors, T cells can be genetically altered to target these antigens and then used for personalized T cell therapy. A method to identify and select peptide antigens that effectively associate with and are presented by host HLA surface molecules originating from tumor cells responsible for the…
Finding biologically relevant cancer markers is key to developing an effective treatment. Once specific antigens have been identified that are present on the cell population responsible for propagating tumors, T cells can be genetically altered to target these antigens and then used for personalized T cell therapy. A method to identify and select peptide antigens that effectively associate with and are presented by host HLA surface molecules originating from tumor cells responsible for the persistence and propagation of a cancer has been developed. The system of using these data to produce T cells engineered to express T cell receptors recognizing the peptide antigens is used in the production of a personalized adoptive T cell therapy for cancer that eliminates the cells capable of tumor propagation and cancer progression. The system is especially useful in the production of cancer treatments to achieve complete durable remission of cancers of epithelial origin
Other inventorsSee patent
Recommendations received
1 person has recommended Joe
Join now to viewOther similar profiles
Explore top content on LinkedIn
Find curated posts and insights for relevant topics all in one place.
View top contentOthers named Joe Laning in United States
6 others named Joe Laning in United States are on LinkedIn
See others named Joe Laning